Satellos Bioscience Inc.
TSX:MSCL.TOBiotechnology
+$0.01 today
- Market cap
- $182.89M
- Beta
- 1.17
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.32
Volume 0.01M
Average 0.02M
MSCL.TO Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Satellos Bioscience Inc.TSX: MSCL.TO
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 69.7% from a year ago
Total assets stood at $75.28M at the end of Q1 FY2026, up 69.7% from a year earlier and up 136.5% from the prior quarter. Over 3 fiscal years it compounded at +72.5% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +69.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 31.83M USD
- Year-over-year change
- —
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.83M | — |
| FY2024 | 2024-12-31 | 73.02M | +64.8% |
| FY2023 | 2023-12-31 | 44.3M | +614.6% |
| FY2022 | 2022-12-31 | 6.2M | -50.7% |
| FY2021 | 2021-12-31 | 12.59M | — |
Total Assets vs competitors
How MSCL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +69.7% is the 2nd highest of 4, against a peer median of +23.4%.
- Over three fiscal years its annual growth of +72.5% compares with a peer median of -27.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $75.28M USD | +69.7% | +72.5% |
| Mar 2026 | CA$31.41M CAD | +23.4% | -27.5% | |
| Apr 2026 | CA$21.38M CAD | +2019.1% | +71.5% | |
| Apr 2026 | CA$1.53M CAD | -60.4% | -75.6% | |
| Peer median (excluding MSCL.TO) | — | +23.4% | -27.5% | |
Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · CAD | FY2024 Dec 2024 · CAD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.87M | 1.92M | 22.07M | 57.66M | 9.79M |
| Short-term Investments | 0 | 0 | 17.52M | 12.2M | 17.87M |
| Net Receivables | 527.98K | 260.44K | 583K | 626K | 369.33K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.57K | 4K | 0 | (6.92K) |
| Total Current Assets | 5.44M | 2.23M | 40.32M | 73.01M | 31.83M |
| Property, Plant & Equipment (Net) | 8.19K | 9K | 19K | 5K | 4.99K |
| Goodwill | 0 | (190) | 0 | 0 | 0 |
| Intangible Assets | 7.14M | 3.92M | 3.92M | 0 | 0 |
| Long-term Investments | 0 | 42K | 41K | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 7.14M | 3.97M | 3.98M | 5K | 4.99K |
| Total Assets | 12.59M | 6.2M | 44.3M | 73.02M | 31.83M |
| Account Payables | 1.13M | 1.47M | 1.04M | 2.97M | 1.77M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | (7.47K) |
| Total Current Liabilities | 2.1M | 2.83M | 3.62M | 5.16M | 4.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.1M | 2.83M | 3.62M | 5.16M | 4.1M |
| Common Stock | 28.32M | 30.21M | 61.92M | 105.73M | 85.67M |
| Retained Earnings | (20.29M) | (31.61M) | (47.5M) | (75.6M) | (81.82M) |
| Accumulated OCI | (1.44K) | 1.09M | 21.24M | (217K) | 13.73M |
| Other Stockholders Equity | 0 | 0 | 0 | 27.62M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 10.48M | 3.37M | 40.67M | 67.86M | 27.73M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | (4.87M) | (1.92M) | (22.07M) | (57.66M) | (9.79M) |
Satellos Bioscience Inc.
TSX:MSCL.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.